Orphenadrine
Disipal, Orphenadrine, Orphengesic (orphenadrine) is a small molecule pharmaceutical. Orphenadrine was first approved as Norflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Orphenadrine (discontinued: Disipal, Norflex, Orphenadrine)
CombinationsOrphengesic (discontinued: Invagesic, Norgesic, Orphenadrine citrate, aspirin, caffeine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Orphenadrine hydrochloride
Orphenadrine citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORFLEX | Bausch Health Companies | N-012157 DISCN | 1982-01-01 | 1 products, RLD |
| NORFLEX | PAI Pharma | N-013055 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Aspirin
+
Caffeine
+
Orphenadrine citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORGESIC | Bausch Health Companies | N-013416 DISCN | 1982-10-27 | 1 products, RLD |
| NORGESIC FORTE | Bausch Health Companies | N-013416 DISCN | 1982-10-27 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| norflex | ANDA | 2020-12-04 |
| norgesic | ANDA | 2024-01-08 |
| norgesic forte | ANDA | 2024-01-27 |
| orphenadrine citrate | ANDA | 2024-12-31 |
| orphenadrine citrate aspirin caffeine | ANDA | 2024-07-25 |
| orphenadrine citrate exended-release | 2008-04-09 | |
| orphenadrine citrate, aspirin and caffeine | ANDA | 2025-01-13 |
| orphengesic forte | ANDA | 2024-12-18 |
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BC: Ethers chemically close to antihistamines, centrally acting muscle relaxants
— M03BC01: Orphenadrine (citrate)
— M03BC51: Orphenadrine, combinations
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04A: Anticholinergic agents
— N04AB: Ethers chemically close to antihistamines, anticholinergic
— N04AB02: Orphenadrine (chloride)
HCPCS
Code | Description |
|---|---|
| J2360 | Injection, orphenadrine citrate, up to 60 mg |
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 3 | 1 | 4 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 2 | 1 | 3 |
| Pain management | D059408 | — | — | — | — | — | 1 | 1 | 2 |
| Low back pain | D017116 | — | M54.5 | — | — | 1 | 1 | — | 2 |
| Back pain | D001416 | — | M54 | — | — | 1 | 1 | — | 2 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | — | 1 | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | — | — | 1 | — | 1 |
| Constipation | D003248 | — | K59.0 | — | — | — | 1 | — | 1 |
| Diverticulitis | D004238 | EFO_1001460 | K57 | — | — | — | 1 | — | 1 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | 1 | 2 |
| Muscle cramp | D009120 | — | — | — | — | 1 | — | 1 | 2 |
| Spasm | D013035 | — | M62.83 | — | — | 1 | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Orphenadrine |
| INN | orphenadrine |
| Description | Orphenadrine is a tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. It has a role as a NMDA receptor antagonist, a H1-receptor antagonist, an antiparkinson drug, a parasympatholytic, a muscle relaxant, a muscarinic antagonist and an antidyskinesia agent. It is a tertiary amino compound and an ether. |
| Classification | Small molecule |
| Drug class | sympathomimetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1C(OCCN(C)C)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 83-98-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL900 |
| ChEBI ID | 7789 |
| PubChem CID | 4601 |
| DrugBank | DB01173 |
| UNII ID | AL805O9OG9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Orphenadrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,252 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
882 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use